Preclinical success with GBP1 knockdown in lung cancer suggests translational potential, but scaling to humans requires overcoming pharmacokinetic hurdles (e.g., half-life, bioavailability), safety concerns (e.g., immunogenicity), and clinical trial design, assessable through phase I/II studies [68]. This evidence concerns the gene GBP1 and lung cancer.